Gossamer Bio (GOSS) Projected to Release Quarterly Earnings on Tuesday

Gossamer Bio (NASDAQ:GOSS) is projected to release its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect Gossamer Bio to post earnings of ($0.08) per share and revenue of $4.2960 million for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, August 7, 2026 at 4:00 PM ET.

Gossamer Bio (NASDAQ:GOSS) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The firm had revenue of $16.95 million during the quarter, compared to the consensus estimate of $4.67 million. On average, analysts expect Gossamer Bio to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Gossamer Bio Price Performance

GOSS stock opened at $0.23 on Tuesday. The stock has a market capitalization of $54.92 million, a P/E ratio of -0.31 and a beta of 2.04. Gossamer Bio has a fifty-two week low of $0.11 and a fifty-two week high of $3.87. The business has a 50-day moving average of $0.18 and a 200-day moving average of $0.80.

Analysts Set New Price Targets

Several equities research analysts have commented on GOSS shares. Leerink Partners upgraded Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $1.00 target price on the stock in a research note on Tuesday. HC Wainwright reaffirmed a “buy” rating on shares of Gossamer Bio in a research note on Monday. Finally, Weiss Ratings downgraded shares of Gossamer Bio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, May 19th. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $3.20.

Hedge Funds Weigh In On Gossamer Bio

A number of large investors have recently modified their holdings of GOSS. Bank of America Corp DE increased its position in shares of Gossamer Bio by 107.2% in the fourth quarter. Bank of America Corp DE now owns 84,788 shares of the company’s stock valued at $77,000 after acquiring an additional 43,866 shares during the last quarter. Invesco Ltd. acquired a new position in Gossamer Bio during the first quarter valued at approximately $48,000. Cubist Systematic Strategies LLC acquired a new position in Gossamer Bio during the first quarter valued at approximately $213,000. Goldman Sachs Group Inc. grew its stake in Gossamer Bio by 720.2% in the first quarter. Goldman Sachs Group Inc. now owns 939,603 shares of the company’s stock valued at $1,034,000 after purchasing an additional 825,047 shares in the last quarter. Finally, Jane Street Group LLC grew its stake in Gossamer Bio by 5,250.1% in the first quarter. Jane Street Group LLC now owns 683,423 shares of the company’s stock valued at $752,000 after purchasing an additional 670,649 shares in the last quarter. 81.23% of the stock is currently owned by institutional investors and hedge funds.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.